Skip to content

A randomised controlled trial on the impact of an AI-assisted pneumonia diagnosis system on the prognosis of haematological patients with pulmonary infections

A randomised controlled trial on the impact of an AI-assisted pneumonia diagnosis system on the prognosis of haematological patients with pulmonary infections

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600124850
Enrollment
Unknown
Registered
2026-05-18
Start date
2026-05-20
Completion date
Unknown
Last updated
2026-05-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung infection

Interventions

AI-assisted diagnosis group:Using AI to assist in the classification of types of lung inflammation
Conventional Diagnosis Group:It is standard practice for a doctor to determine the type of lung inflammation

Sponsors

The First Affiliated Hospital of Soochow University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Patients aged 18 years or older; 2. Patients with a clinical suspicion or provisional diagnosis of pulmonary infection; 3. Patients with a clinical suspicion or provisional diagnosis of a malignant haematological disorder, including leukaemia, lymphoma, multiple myeloma, etc; 4. Patients who underwent a chest CT scan during the study period, and whose baseline chest CT scan revealed new or progressive pulmonary lesions such as oedema, consolidation, nodules or halo signs, consistent with the radiological features of pulmonary infection; 5.Microbiological or pathological confirmation must be obtained after the baseline CT scan.

Exclusion criteria

Exclusion criteria: 1. Patients with severe cardiopulmonary insufficiency, chest deformities or other conditions that may affect the quality of CT images; 2. Pregnant or breastfeeding women (where the CT scan may affect the foetus or infant) 3. Patients concurrently suffering from other active pulmonary diseases (such as active tuberculosis, obstructive pneumonia caused by lung cancer, or acute pulmonary embolism), the radiological manifestations of which may significantly interfere with the assessment and diagnosis of fungal lesions in the lungs; 4. Patients who are unable to provide complete clinical data or who refuse to cooperate with the study.

Design outcomes

Primary

MeasureTime frame
100 day all-cause mortality;

Secondary

MeasureTime frame
Rate of severe cases conversion;Changes in pneumonia-related clinical scores;AI Diagnostic Performance;Changes in hematological-related indicators;

Countries

China

Contacts

Public ContactLi Yonggang

The First Affiliated Hospital of Soochow University

liyonggang224@163.com+86 512 6797 3045

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: May 30, 2026